Hoboken, NJ — July 6, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. This is the third of six potential dose steps and follows the successful completion of…
Hoboken, NJ — June 8, 2011 — Anavex Life Sciences Corp., (“Anavex”) (OTCBB: AVXL) today announced the initiation of scale-up manufacturing of ANAVEX 1-41, its lead compound for a range of important neurological diseases and a potential back-up compound to ANAVEX 2-73 in Alzheimer’s disease. “This is an important step in the advancement of our…
Hoboken, NJ — May 23, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the first group of healthy human volunteers in the initial…
Hoboken, NJ — May 17, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated for the first time in more than 25 years. The new guidelines discuss…
Hoboken, NJ — May 13, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the appointment of Robert Chisholm to the Board of Directors. As a finance and administration executive with more than 25 years of experience, Mr. Chisholm brings to Anavex significant expertise in corporate finance, strategic business initiatives and the unique…
Expert Opin Ther Targets. 2011 May ; 15(5): 557–577. doi:10.1517/14728222.2011.560837. Hayashi Teruo*, Tsai Shang-Yi, Mori Tomohisa, Fujimoto Michiko, and Su Tsung-Ping View Poster
Hoboken, NJ — April 20, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease. “We are pleased that the first volunteers have been dosed with the…
Hoboken, NJ — April 8, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the appointment of Dr. Christopher Shackleton as an advisor to the Company. Dr. Shackleton is a prominent, uniquely qualified physician and surgeon, clinical investigator, information technologist, and corporate finance/healthcare solutions consultant. He holds triple specialist credentials in medical and…
Hoboken, NJ — April 6, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is scheduled to hold its annual meeting of stockholders on Monday, April 11, 2011 at 11:00 a.m. EDT at 50 Harrison Street, Hoboken, New Jersey. Stockholders of record on the record date, which was set as February 24, 2011 at close…
Hoboken, NJ — March 31, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which…
